Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

61 results about "Dna quantitation" patented technology

Method for Treating Systemic Bacterial, Fungal and Protozoan Infection

A treatment for the diseases that are accompanied by quantitative and qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent must be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNASE enzyme may be further applied in a dose and regime that provide a DNA hydrolytic activity measured in blood plasma exceeding 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.
Owner:CLS THERAPEUTICS

Detection method of miRNA absolute expression level in biological sample

InactiveCN101363057AMake up for the shortcomings that can only reflect relative differencesReliable analysisMicrobiological testing/measurementMaterial analysis by optical meansLoss rateRNA extraction
The invention relates a method for measuring miRNA absolute expression quantity in biological samples, which comprises the following steps: 1) material selection: 8 weeks and 40 weeks of mouse brain tissues are selected; 2) total RNA extract; 3) RT(reverse transcription)-Polymerase Chain Reaction (PCR); 4) quantifying DNA; 5) drawing specification curve; 6) data processing: loss rate and average loss rate of little RNA is figured out in the process of extracting RNA according to the copy number of spike RNA in the extracted total RNA which is detected by the PCR; the expression quantity of every initial cell of the little RNA at the levels of DNA and RNA is figured out according to the cell number of original sample that is respectively expressed from the levels of DNA and RNA. The method has the advantages of miRNA expression quantity is faithfully transformed into the absolute expression quantity in the original sample through the cell number in the sample homogenate which is worked out from the two levels of DNA and RNA; the disadvantage that relative differentiation can only be reflected by taking housekeeping genes as an internal reference, and the analysis is truer and more reliable from the two levels of DNA and RNA.
Owner:ZHEJIANG SCI-TECH UNIV +1

Kit for detecting DNA residues of CHO cell and using method thereof

The invention relates to a kit for detecting deoxyribose nucleic acid (DNA) residues of a Chinese hamster ovary (CHO) cell and a using method thereof. The kit comprises DNA extracting solution, polymerase chain reaction (PCR) amplification reaction liquid, a DNA quantitative reference product of a CHO cell genome, a negative quality control product, a positive quality control product and DNA diluent. In the kit, EvaGreen is used as a fluorescent dye, and the DNA of the CHO cell genome is detected by a real-time quantitative PCR technology; and products such as a treatment protein medicament, a recombinant vaccine, a monoclonal antibody and the like from the CHO cell can be accurately and quantitatively detected.
Owner:SHANGHAI HENLIUS BIOTECH INC

DNA or RNA detection and/or quantification using spectroscopic shifts or two or more optical cavities

A spectroscopic technique for high-sensitivity, label free DNA quantification uses a shift in an optical resonance (whispering gallery mode, WGM) excited in a micron-sized optical cavity (e.g., a silica sphere) to detect and measure nucleic acids. The surface of the silica sphere is chemically modified with oligonucleotides. Hybridization to the target DNA leads to a red-shift of the optical resonance wavelength. The sensitivity of this resonance technique is higher than most optical single-pass devices such as surface plasmon resonance biosensors. Each microsphere can be identified by its unique resonance wavelength. Specific, multiplexed DNA detection may be provided by using two or more microspheres. The multiplexed signal from two or more microspheres illustrates that a single nucleotide mismatch in an 11-mer oligonucleotide can be discriminated with a high signal-to-noise of 54. This all-photonic WGM biosensor can be integrated on a chip, such as a semiconductor chip, which makes it an easy to manufacture, analytic component for a portable, robust lab-on-a-chip device.
Owner:POLYTECHNIC INSTITUTE OF NEW YORK UNIVERSITY

Quantitative plasmid DNA (Deoxyribonucleic Acid) detection kit

InactiveCN102980878AMake up for the shortcomings of not being able to quantify quality DNAHigh sensitivityFluorescence/phosphorescenceFluorescencePlasmid dna
The invention provides a quantitative plasmid DNA (Deoxyribonucleic Acid) detection kit which has the characteristics of adopting a plasmid DNA standard substance to accurately quantify by using an ultrasonic-isotope dilution mass-spectrography with high accuracy, and making up the defect that a conventional kit cannot quantify the plasmid DNA. The invention further provides a plasmid DNA quantitative detection method which comprises the following steps of: respectively measuring fluorescence signal strengths of the plasmid DNA standard substances of different concentrations; drawing a concentration-fluorescence signal strength standard curve; subsequently measuring the fluorescence signal strength of a plasmid DNA sample to be measured; and accurately calculating the DNA concentration of the sample to be measured according to the drawn standard curve. According to the method and the kit, standard plasmids are adopted to be used as the DNA standard to quantify in a fluorescent dye method for the first time with high sensitivity, and DNA as low as 1pg can be detected; the linear range is wide, and plasmid DNA of 0.25-1000ng / Ml can be detected; and the standard plasmids are quantified by using the ultrasonic-isotope dilution mass-spectrography, and the quantitative value obtained is low in uncertainty and high in accuracy.
Owner:NAT INST OF METROLOGY CHINA

Cell nucleus DNA (Deoxyribose Nucleic Acid) staining method

InactiveCN102967499AEasy to fixReduce acidolysisPreparing sample for investigation3-deoxyriboseFeulgen stain
The invention discloses a cell nucleus DNA (Deoxyribose Nucleic Acid) staining method. The cell nucleus DNA staining method is characterized by comprising the following steps: 1, fixation: sequentially placing sample slices into a BS fixing solution at the temperature of 30-40 DEG C to fix for 20-30 minutes, and rinsing; 2, hydrolyzation: completely fixing the sample slices, hydrolyzing in 5N hydrochloric acid at the temperature of 30-40 DEG C for 20-30 minutes, and rinsing; 3, staining: after the hydrolyzation is completed, staining in a Thionin staining solution at the temperature of 30-40 DEG C for 30-40 minutes, and rinsing; 4, after the staining is completed, dewatering by adopting fast gradient ethanol, and mounting. In conclusion, compared with other Feulgen staining methods, the cell nucleus DNA cell nucleus DNA has the obvious advantages of practicability, stability, efficiency, cost saving, repeatability, compatibility of automated equipment and the like and can meet the requirement of clinical DNA quantitative cytology on fast diagnosis.
Owner:MOTIC XIAMEN MEDICAL DIAGNOSTICS SYST

Preparation method of next-generation sequencing library

The invention discloses a preparation method of a next-generation sequencing library. The preparation method is carried out according to the following steps: quantifying DNA (Deoxyribonucleic Acid); adding a needed DNA linker sequence in a sequencing process at two ends of a DNA fragment to be detected; detecting the concentration of a DNA library and a DNA fragment length distribution mode; calculating a mixing ratio of the DNA library and mixing; selecting a fragment of a mixed library; detecting and quantifying the selected DNA library; sequencing the selected DNA library. According to themethod disclosed by the invention, a plurality of libraries are mixed together after being subjected to PCR (Polymerase Chain Reaction) and are subjected to primary fragment sorting and Q-PCR (Quantitative-Polymerase Chain Reaction) quantifying, so that the working amount is greatly reduced; the distribution of a final sequencing data quantity in different samples is not remarkably influenced.
Owner:AGRI GENOME INST OF SHENZHEN CHINESE ACADEMY OF AGRI SCI

Body fluid circulation DNA quantitative determination method and kit

ActiveCN106399536AAvoid mutual interferenceMutual interference will not causeMicrobiological testing/measurementDetection biasPlasmid dna
The invention discloses a body fluid circulation DNA quantitative determination method and kit. The method includes steps of selecting artificial single copy house-keeping gene Beta-action as the detection target gene, and artificially compounding a dual-chain DNA segment with length of 45 bp, wherein it includes sequences with the same 25 bp and Beta-action genes, and recombining to a plasma carrier T-Vector pMD 20 and obtaining the recombined plasmid DNA as an interior label, and feeding a certain quantity of interior label to a body fluid sample to be tested; synchronously storing with the body fluid circular DNA, and performing nucleic acid extraction and purification, and fluorogenic quantitative PCR amplification, so as to perform the body fluid circulation DNA quantitative analysis. Through setting up a special internal label, the method eliminates the detection bias caused by nucleic acid degradation, extraction loss and PCR amplification efficiency before and in body fluid sample analysis, and can perform more stable and exact quantitative determination on the body fluid circulation DNA.
Owner:JIANGSU CODE BIOMEDICAL TECH CO LTD

Preparation method of plasmid deoxyribonucleic acid (DNA) quantitative detection standard

The invention discloses a preparation method of a plasmid deoxyribonucleic acid (DNA) quantitative detection standard for the first time. Plasmid DNA is ultrasonically treated into fragments with the lengths of less than 200bp, and is subjected to enzymolysis, a nucleotide marked by a nucleotide standard and an isotope is taken as an internal standard, and mononucleotides are separated and accurately quantified by using high-performance liquid chromatography-mass spectrometry. An optimal condition for the ultrasonic treatment of the plasmid DNA and a condition for the high-performance liquid chromatographic separation of four nucleotides are created. The method is high in precision and accuracy, namely the nucleotide standard is adopted, and dependence on a DNA standard is eliminated, so that a measurement result can be traced back to a nucleotide certified standard material, and the reliability and a traceable source of the measurement result are ensured. The method can be used for absolutely quantifying the plasmid DNA and preparing the plasmid DNA quantitative detection standard.
Owner:NAT INST OF METROLOGY CHINA

Semi-automatic smearing method of hydrothorax and ascite liquid-base cytology

The invention discloses a semi-automatic method for producing pleural and ascites liquid-based cytology. After the sample is collected, it is placed in a preservation solution bottle, and the preservation solution bottle is placed on a vibrator, and then passed through a centrifuge tube with a sharp bottom in a centrifuge. Add the cell dispersion liquid into the sampler, absorb and discard the supernatant in the test tube, remove the remaining liquid, and place the centrifuged sample on the sample delivery device of the film maker, and each sample passes through the spectrometer in turn, and the sample is aspirated The sample is placed on the corresponding slide in the transfer module, and the dried slide can be used for Papanicolaou staining or HE staining for cytological diagnosis, and Feulgen special staining for DNA quantitative analysis. The present invention is mainly used to improve and solve the problems existing in the non-cervical cell extraction, including the small number of cells, the overlapping of cells, the long production time, the background impurities of the produced films, and the low degree of automation. The quality of slides is improved, the number and distribution of cells on slides are more uniform, easy to use, and has the value of popularization and application.
Owner:刘崇梅

Primer pair, probe and kit used for quantitative detection total DNAs of HIV-1 and capable of covering multiple subtypes of HIV-1

The invention discloses a primer pair, probe and kit used for quantitative detection total DNAs of HIV-1 and capable of covering multiple subtypes of HIV-1. The sequence of the upstream primer HIV-U1of the primer pair is as shown in SEQ ID No. 1; the sequence of the downstream primer HIV-R1 of the primer pair is as shown in SEQ ID No. 2; the sequence of the probe Probe-HIV is as shown in SEQ ID No. 3. According to the invention, degenerate primers are utilized for high-sensitivity high-specificity detection of HIV DNA, and 12 common subtypes of HIV and rare HIV subtypes can be successfully detected, so the detection kit of the invention has wider subtype detection coverage compared with other conventional commercial detection kits. The primer pair, probe and kit provided by the inventioncan be used for quantification of total HIV DNAs of current prevalent HIV strains in China. A method provided by the invention is simple to operate, can complete procedures from sample DNA extractionto real-time fluorescent quantitative PCR amplification in one day, has low price, can be used for monitoring the persistent infection status of HIV-infected individuals in large cohorts, evaluating the effect of cART treatment, and is also applicable to auxiliary diagnosis of early HIV infection and diagnosis of neonatal infection in HIV-positive mothers.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV

Therapeutical effect of atabrine and substitutes thereof on hepatitis B

By adopting methods of fluorescent quantitation PCR, fluorescent quantitation RT-PCR, HBV DNA quantitation, HBsAg quantitation, HBeAg quantitation, cccDNA quantitation, Northern blot, Southern blot, Western blot, immunohistochemistry, and the like in the research and using the maintenance dose within the treating dose range for a long time (30-60 days), supernatant HBV DNA HBsAg HBeAg cultured by HepG-2.2.15 cells can completely disappear, HBsAg, HBeAg, HBcAg, and the like in the cells are completely turned to be negative, HBV DNA is in a high inhibited state, HBV cccDNA is completely negative, fluorescent quantitation RT-PCR detection finds that the mRNA for expressing HBsAg and HBcAg antigens in the cells is completely negative, and in addition, the curative effect of the atabrine is 30 times that of lamivudine as a first-line drug for resisting HBV in current clinic. In order to illustrate the action mechanism of the atabrine and the pyronaridine as a drug belonging to the same kind with the atabrine, an HBV genome is divided into 3 segments which are respectively inserted into an Xb1 position on a luciferase report carrier PGL3, a multifunctional microplate reader detects and finds that the light production value of the luciferase is remarkably reduced, which shows that the molecules of the atabrine and the pyronaridine as a drug belonging to the same kind with the atabrine can be nonspecifically combined with the HBV DNA in the cells, thereby inhibiting the copying of the virus and ensuring that the HBV DNA content of the virus in cells copied by the filial generation is reduced till to disappear. The patent requires protecting the application of 3 linked benzyl structures (named as ethyleneimine) and radicals such as CH3O-,-NH-, CL-, and the like for resisting HBV virus in clinic.
Owner:蔡荣 +3
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products